2-AMINO-5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-OL | 40775-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 2-AMINO-5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-OL
• 英文别名: 2-amino-5-methyl-[1,2,4]triazolo[1,5-a]-pyrimidin-7(3H)-one；2-amino-5-methyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one；2-Amino-7-hydroxy-5-methyl-s-triazolo[1,5-a]pyrimidine；2-Amino-5-methyl-7-hydroxy-1,3,4-triaza-indolizin
• CAS: 40775-79-9
• 化学式: C₆H₇N₅O
• mdl: MFCD00460137
• 分子量: 165.154
• InChiKey: YMISIYGVEADHLQ-UHFFFAOYSA-N

物化性质

• 熔点：
  >290 °C(Solv: water (7732-18-5))
• 密度：
  1.83±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.28
• 重原子数：
  12.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  89.33
• 氢给体数：
  2.0
• 氢受体数：
  6.0

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-AMINO-5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-OL 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 3.5h， 生成 methyl (R)-2-[(2-amino-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetate
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS
  [FR] BICYCLO-COMPOSÉS DE TRIAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及一种用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的式（I）的取代三唑杂双环化合物，该化合物可用作治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的化合物的用途。

  公开号：

  WO2017000277A1
• 作为产物：
  描述：

  3,5-二氨基-1,2,4-三氮唑 、 乙酰乙酸甲酯 在 溶剂黄146 作用下， 反应 0.5h， 生成 2-AMINO-5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-OL
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS
  [FR] BICYCLO-COMPOSÉS DE TRIAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及一种用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的式（I）的取代三唑杂双环化合物，该化合物可用作治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的化合物的用途。

  公开号：

  WO2017000277A1

文献信息

• Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
  作者：Lewis R. Vidler、Panagis Filippakopoulos、Oleg Fedorov、Sarah Picaud、Sarah Martin、Michael Tomsett、Hannah Woodward、Nathan Brown、Stefan Knapp、Swen Hoelder

  DOI：10.1021/jm4011302

  日期：2013.10.24

  Bromodomains (BRDs) are epigenetic readers that recognize acetylated-lysine (KAc) on proteins and are implicated in a number of diseases. We describe a virtual screening approach to identify BRD inhibitors. Key elements of this approach are the extensive design and use of substructure queries to compile a set of commercially available compounds featuring novel putative KAc mimetics and docking this

  溴结构域 (BRD) 是表观遗传阅读器，可识别蛋白质上的乙酰化赖氨酸 (KAc)，并与许多疾病有关。我们描述了一种虚拟筛选方法来识别 BRD 抑制剂。这种方法的关键要素是广泛设计和使用子结构查询来编译一组具有新型推定 KAc 模拟物的市售化合物，并将该组对接以进行最终化合物选择。我们通过将其应用于 BRD4 的第一个 BRD 来描述该方法的验证。对 143 种化合物的选择和测试导致发现了六种新的热门产品，其中包括四种前所未有的 KAc 模拟物。我们解决了四个命中的晶体结构，确定了它们的结合模式，并通过合成和购买衍生物提高了它们的效力。
• Cephalosporin derivatives
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US04888332A1

  公开（公告）日：1989-12-19

  The present invention relates to novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof. The novel cephalosporin derivatives according to the present invention contain condensed heterocyclic groups, particularly a triazolopyrimidine ring or a thiadiazolopyrimidine ring as substituents at the 3-position of the cephem skeleton, and a hydroxyimino, an alkyloxyimino or an acyloxyimino moiety as substituents at the 7-position of the cephem skeleton. The compounds of the present invention containing the aforementioned substituents have a strong antibacterial activity against gram-negative bacteria and also against gram-positive bacteria including methicillin-resistant Staphylococcus aureus. These compounds are extremely useful for the treatment of infectious diseases.

  本发明涉及新型头孢菌素衍生物、其制备方法、以新型头孢菌素衍生物作为活性成分的预防和/或治疗传染病的组合物，以及头孢菌素衍生物合成中的中间体化合物和其制备方法。本发明的新型头孢菌素衍生物包含紧缩杂环基团，特别是三唑嘧啶环或噻唑嘧啶环作为头孢菌素骨架的3位取代基，并且在头孢菌素骨架的7位取代基是羟肟基、烷氧基肟基或酰氧基肟基。本发明中含有上述取代基的化合物对革兰氏阴性菌和包括甲氧西林耐药金黄色葡萄球菌在内的革兰氏阳性菌具有强大的抗菌活性。这些化合物对于治疗传染病非常有用。
• Intermediates cephalosporin derivatives
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US05064953A1

  公开（公告）日：1991-11-12

  The present invention relates to novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof. The novel cephalosporin derivatives according to the present invention contain condensed heterocyclic groups, particularly a triazolopyrimidine ring or a thiadiazolopyrimidine ring as substituents at the 3-position of the cephem skeleton, and a hydroxyimino, an alkyloxyimino or an acyloxyimino moiety as substituents at the 7-position of the cephem skeleton. The compounds of the present invention containing the aforementioned substituents have a strong antibacterial activity against gram-negative bacteria and also against gram-positive bacteria including methicillin-resistant Staphylococcus aureus. These compounds are extremely useful for the treatment of infectious diseases.

  本发明涉及新型头孢菌素衍生物，其制备方法，包含新型头孢菌素衍生物作为活性成分的预防和/或治疗传染病的组合物，以及头孢菌素衍生物合成中的中间体化合物和其制备方法。本发明中的新型头孢菌素衍生物含有紧凑的杂环基团，特别是三唑嘧啶环或噻唑嘧啶环作为头孢菌素骨架的3位取代基，并且羟肟基，烷氧肟基或酰氧肟基作为头孢菌素骨架的7位取代基。本发明中含有上述取代基的化合物对革兰氏阴性菌和包括甲氧西林耐药金黄色葡萄球菌在内的革兰氏阳性菌具有强烈的抗菌活性。这些化合物对于治疗传染病非常有用。
• Cephalosporin derivatives, processes for producing the same and compositions containing them
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0150507A2

  公开（公告）日：1985-08-07

  Novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in synthesis of cephalosporin derivative and processes for producing thereof are disclosed. The novel cephalosporin derivatives contain condensed heterocyclic groups, particularly a triazolopyrimidine ring or a thiadiazolopyrimidine ring as substituents at the 3-position of the cephem skeleton, and a hydroxyimino, an alkyloxyimino or an acyloxyimino moiety as substituents at the 7-position of the cephem skeleton. These compounds have a strong antibacterial activity against gram-negative bacteria and also against gram-positive bacteria including methicillin-resistant Staphylococcus aureus. They are extremely useful for the treatment of infectious diseases.

  本发明公开了新型头孢菌素衍生物、其制备工艺、包含新型头孢菌素衍生物作为活性成分的预防和/或治疗传染病的组合物，以及合成头孢菌素衍生物的中间化合物及其生产工艺。 新型头孢菌素衍生物含有缩合杂环基团，特别是在头孢骨架的 3 位上含有三唑嘧啶环或噻二唑嘧啶环作为取代基，在头孢骨架的 7 位上含有羟基亚氨基、烷氧基亚氨基或酰氧基亚氨基作为取代基。 这些化合物对革兰氏阴性菌和革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌）具有很强的抗菌活性。它们对治疗传染病非常有用。
• Substituted triazolo bicyclic compounds as PDE2 inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10357481B2

  公开（公告）日：2019-07-23

  The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式 I 的取代三唑并双环化合物，其可作为治疗剂用于治疗与磷酸二酯酶 2 (PDE2)相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。